WebNov 10, 2024 · Neumifil is a novel, engineered multivalent carbohydrate binding molecule (mCBM), generated using Pneumagen's proprietary GlycoTarge technology that acts by stopping viruses at the site of ... WebMay 27, 2024 · Neumifil is a first-in-class Carbohydrate-Binding Modules, generated using the Company’s proprietary GlycoTarge™ platform. It is being developed for the universal treatment of respiratory tract infections caused by Influenza Virus and Respiratory Syncytial Virus, and now coronaviruses including SARS-CoV-2, the cause of COVID-19.

Our Science – Pneumagen

WebApr 28, 2024 · Pneumagen is using its platform technology, GlycoTarge, to develop glycan targeted carbohydrate-binding module domains (mCBMs) derived from bacterial glycosidases as a new universal therapeutic modality for the prevention and treatment of respiratory tract infections (RTIs). These engineered mCBMs have been shown to … WebJan 21, 2024 · Led by Douglas Thomson, CEO, Pneumagen is a spin-out from the University of St Andrews in Scotland which is using its platform technology, GlycoTarge, to develop glycan targeted carbohydrate ... publix lysol spray

Triglyceride - Wikipedia

WebApr 28, 2024 · Pneumagen, a University of St Andrews spin-out company, carried out three separate in-vitro studies into preventing coronavirus infections, including Sars-CoV-2 … WebJun 9, 2024 · Glycogen is a large, branched polysaccharide that is the main storage form of glucose in animals and humans. Glycogen is as an important energy reservoir; when energy is required by the body, … WebSep 10, 2024 · 10 th September 2024 – St Andrews, Scotland – Pneumagen Ltd, focused on treating infectious disease and oncology by targeting the human glycome, today announced in vivo data on its lead product, Neumifil™, generated from its proprietary GlycoTarge platform.. Neumifil is a first-in-class mCBM40 being developed for the … seasonal flowers in january